In this contribution to the Fall 2026 issue of DDW, Thomas Edwards, Partnering Lead for C-Further, examines why childhood cancer treatments lag behind adult treatments and what needs to change.

Childhood cancer is one of the most underserved areas in oncology

Cancer remains the leading disease-related cause of death in childhood, and yet from 2007 to 2022, only two drugs were approved exclusively for childhood cancer by the EMA and five by the FDA1. In contrast, the FDA issued more than 60 oncology approvals in 2024 alone2.

As a result of the lack of new approvals, the standard of care for most children and young people with cancer remains decades-old chemotherapeutic agents. While these have dramatically improved survival, they carry short-term toxicities, including a heightened risk of serious infection during periods of immune suppression, that are distressing but generally transient. Much less appreciated are the long-term consequences that often go unnoticed for years. By age 45, as many as 80% of childhood cancer survivors will face serious health complications as a result of their treatment, including chronic illness, neurocognitive impairment, or secondary cancers3.

Despite this toxicity burden, chemotherapy still fails many patients. With few alternative options in development, relapsed patients are often enrolled in early phase trials of repurposed adult cancer drugs. Yet these trials are largely ineffective: a meta-analysis in solid tumours found only a 4% objective response rate and under four months of median progression-free survival, substantially worse than the nearly 20% response rate seen in pooled analyses of adult Phase I trials4,5.

Unlike most adult cancers, which typically develop through the gradual accumulation of mutations over time, many childhood cancers arise when a small number of genetic or epigenetic alterations disrupt the developmental programmes of growing cells. This can create a more direct relationship between the initiating alteration and the cancer’s biology, although it does not make the disease inherently simpler to understand, and its treatment requires fundamentally different therapeutic strategies. Roughly half of paediatric tumours contain potentially druggable targets6, but only a few ever attract the investment needed to create drugs. So, if the science exists, why aren’t medicines following?

Market failure is the default

With smaller patient populations and potentially limited commercial returns as headwinds, many promising discoveries struggle to attract the capital necessary to overcome the translational gap between fundamental research and investable drug development.

Classical discounted cash flow analysis illustrates that under conventional investment structures, paediatric oncology most often generates a negative risk-adjusted net present value. This is particularly true for complex, personalised therapies, which have changed the face of cancer treatment for adults. A purely end-to-end commercial model will not deliver therapies to children – the return on investment is too low.

These areas are where specialised not-for-profit organisations and governments often ‘step-in’. However, the fragmented nature of the funding environment means that as a share of cancer R&D funding, paediatric oncology receives only a small fraction of what is needed to meaningfully move the dial. In the UK, a recent analysis showed that about 2% of annual cancer research investment is dedicated to children’s cancers, while in the US, only about 4% of the National Cancer Institute’s budget goes to paediatric cancer7,8. This chronic underfunding persists despite high-level commitments on both sides of the Atlantic. The US reignited its Cancer Moonshot in 2022, setting a goal to halve the cancer death rate within 25 years9, while the UK published its National Cancer Plan for England in February 2026, including a dedicated chapter for children and young people for the first time10. Ambition, it seems, still outpaces allocation.

A path forward

However, the odds can be changed by flipping four key levers. The earliest, riskiest stages of drug discovery could still be funded by philanthropic capital, allowing commercial investors to enter later once technical uncertainty has been reduced. Developers can also realise value earlier by pursuing adult cancers as secondary applications, generating revenue in parallel with paediatric approval. Blended financing structures, meanwhile, can employ mission-driven capital to absorb early losses and attract return-seeking investors once an asset is de-risked. Finally, active portfolio management can concentrate resources on the most promising assets, rather than spreading bets thinly across a series of isolated shots on goal.

Signs of promise amongst strong headwinds 

Although the commercial reality often falls short, the sector is moving from decades of slow but incremental progress to renewed momentum. This was exemplified during the first half of 2026, on three fronts at once: coordination, capital, and market validation.

On coordination: in March 2026, the international paediatric oncology drug development community convened in New York to tackle a familiar problem: cancer compounds with existing adult safety data, shelved for commercial rather than scientific reasons. Participants agreed to build a turnkey pathway to revive these deprioritised assets for children.

On capital: C-Further, a mission-driven joint venture founded by three of the UK’s most influential not-for-profit organisations*, has launched its own pipeline of therapeutics dedicated to children and young people’s cancer, moving beyond repurposing adult drugs to targeted de novo therapeutic discovery. It identifies promising start-points in academia and industry and works to co-develop, accelerate, and de-risk them on the path to commercial viability.

On validation: in April 2026, Servier completed a $2.5 billion acquisition of Day One Biopharmaceuticals, securing OJEMDA, an approved therapy for paediatric low-grade glioma, one of the most common childhood brain tumours. It is a clear signal that paediatric oncology assets can command genuine commercial premiums from select pharma, once significant de-risking has taken place.

Amongst complexity, an opportunity to stand out?

Consistent with drug discovery and development more broadly, even well-resourced players routinely fail to get innovation to patients. Yet for some specialised biotech and pharma, developing new medicines for childhood cancer may be emerging as a genuinely differentiated strategy.

Paediatric tumours typically carry a lower mutational burden than adult cancers, and a subset are driven by a single dominant genetic lesion. This can simplify target identification and validation though the resulting targets, often fusion transcription factors or chromatin regulators, have historically been difficult to drug directly. Advances in modality and platform technology over the last five to 10 years, however, are making previously “undruggable” paediatric drivers increasingly tractable, opening a genuine window for mechanism-of-action therapeutics. Although the target patient population is small and recruitment can be rate-limiting, cohorts are often concentrated at a handful of specialist hubs with the right expertise, infrastructure and networks, which can support the initiation of high-quality and safe trials.

Layered on top is a meaningful incentive stack: extended exclusivity, tax credits, fee waivers, and a Priority Review Voucher that can convert directly into liquidity. Combined with the pricing power selective pharma has recently shown it’s willing to pay for validated paediatric oncology assets, the economics are becoming interesting, even if the underlying regulatory incentives remain in flux.

Those benefits don’t outweigh the hurdles on their own, but they may be enough for some to find a differentiated and clearly articulated way to demonstrate the value of their science. The most compelling opportunity sits with biotechs holding a deprioritised adult asset with paediatric mechanistic relevance, and platform companies looking to validate a technology’s versatility across indications, alongside specialty pharma and early-stage companies seeking a fast, orphan-eligible proof point. For any of them, mission-driven drug discovery engines such as C-Further now offer a credible route back into development, alongside an increasingly receptive regulatory environment.

Momentum is not a system…yet

Addressing sustainably the heart of this systemic problem is likely to require more than smart funding models, isolated initiatives or company-level strategies.

What is needed are frameworks robust enough to stop promising assets from being shelved whenever commercial priorities shift elsewhere, so that discoveries made still have a chance to benefit young patients. As noted above, the same narrow mutational burden that simplifies target identification also means a drug that fails in an adult trial may still work in children – precisely the logic behind rescuing stalled assets.

Policy is beginning to catch up. The United States’ RACE for Children Act shows regulation can accelerate paediatric development and the recently signed Mikaela Naylon Give Kids a Chance Act reauthorises the Priority Review Voucher programme, which continues to offer meaningful incentives, selling for upward of $200 million. But compliance-driven paediatric studies are not the same as design-led paediatric product development. The shift isn’t confined to the US: Australia has launched a national childhood, adolescent and young adult cancer roadmap and the UK has enacted its own Rare Cancers Act, with consultation on further regulatory reform now underway.

None of this adds up to a system yet, but the direction of travel is unmistakable. Biotech, academia, investors and policymakers now need to treat paediatric oncology as a shared market to build and an opportunity to seize, not an obligation to fulfil or a liability to avoid. It has been dismissed as a niche for too long. With the right capital structure, partnerships, and policy, paediatric oncology can become scientifically viable and economically sustainable.

About the author

As a Business Development Executive at Cancer Research Horizons (the innovation arm of Cancer Research UK), Thomas Edwards leads business development for C-Further, and is responsible for building strategic partnerships, negotiating agreements and securing funding. With extensive experience in life sciences commercialisation, Edwards specialises in dealmaking, financial modelling, and translating innovation into patient impact.

References

  1. WHO. Regulatory approval status of drugs in paediatric cancer trials [Internet]. 2023 [cited 2026 Aug 11]. Regulatory approval status of drugs in paediatric cancer trials. Available from: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/pediatric-cancer-drug-approval-overview
  2. FDA [Internet]. FDA; 2026 [cited 2026 Aug 11]. Oncology (Cancer)Approval Notifications. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
  3. Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). The Lancet. 2017;390(10112):2569–82.
  4. Dorris K, Liu C, Li D, et al. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatr Blood Cancer. 2017;64(3):e26258.
  5. Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018;378(23):2242–3.
  6. George SL, Izquierdo E, Campbell J, et al. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. Eur J Cancer. 2019;121:224–35.
  7. Great Ormond Street Hospital Children’s Charity. Only 2% of cancer research funding is for children’s cancer [Internet]. [cited 2026 Aug 11]. Only 2% of cancer research funding is for children’s cancer. Available from: https://www.gosh.org/news/only-2p-out-of-every-1-spent-on-cancer-research-goes-exclusively-towards-the-fight-against-childrens-cancer/
  8. Little Warrior Foundation | Cure for Childhood Cancer [Internet]. [cited 2026 Aug 11]. #MoreThan4: The State of Pediatric Cancer Funding in the US. Available from: https://www.littlewarrior.org/blog/morethan4-the-state-of-pediatric-cancer-funding-in-the-us
  9. Cancer MoonshotSM – NCI [cgvArticle] [Internet]. 2025 [cited 2026 Aug 11]. Located at: nciglobal,ncienterprise. Available from: https://www.cancer.gov/research/progress/moonshot-cancer-initiative
  10. GOV.UK [Internet]. 2026 [cited 2026 Aug 11]. National Cancer Plan for England. Available from: https://www.gov.uk/government/publications/national-cancer-plan-for-england

* Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity

From DDW Volume 27 – Issue 4, Fall 2026 – Read the digital issue here.